Idacta mAb INT-001 represents the interesting therapeutic approach for treating specific blood-related malignancies. The antigen-binding protein shows an unique mode of action, mainly targeting CD-38, a exterior https://inesppql887626.wikiannouncement.com/10380303/idacta_mab_int_001_the_novel_immunoglobulin_in_progression